b-Hydroxyisovalerylshikonin (b-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in b-HIVS-induced apoptotic process, we performed cDNA array analysis and found that b-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10 À6 m b-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by b-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both b-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, b-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the b-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by b-HIVS might play a critical role in the induction of apoptosis.
Introduction
Apoptosis, known also as programmed cell death, was originally defined in terms of characteristic changes in cell morphology (Kerr et al., 1972; Wyllie et al., 1984) . It has been implicated in a variety of biological process, such as embryogenesis (Hurle et al., 1981) , regulation of the immune system (Ucker, 1987) , cytotoxic cell killing of virally infected cells (Laurent-Crawford et al., 1991) , and the elimination of damaged cells. The importance of apoptosis has been emphasized by recent demonstrations that various chemotherapeutic anti-cancer agents, such as cisplatin (Kaufmann, 1989; Barry et al., 1990; Evans and Dive, 1993) , adriamycin (Friesen et al., 1996) , and taxol (Bhalla et al., 1993) , induce apoptosis in cancer cells. We have identified several differentiationor apoptosis-inducing compounds (Sakai et al., 1993 (Sakai et al., , 1994 Ohizumi et al., 1995; Masuda et al., 1995 Masuda et al., , 1997 Watabe et al., 1996) and found recently that bhydroxyisovalerylshikonin (b-HIVS) has potent apoptosis-inducing activity (Hashimoto et al., 1999) . We isolated b-HIVS from a Chinese plant, Lithospermum erythrorhizon, and found that it had the strongest apoptosis-inducing activity of a variety of derivatives of shikonin in HL60 cells (Hashimoto et al., 1999) . In the present study, we tried to identify the gene that is involved in b-HIVS-induced apoptosis to clarify the molecular mechanisms of apoptosis. Gene-expression arrays have recently been developed as highly effective tools for the profiling of gene expression (Chalifour et al., 1994; Schena et al., 1995) , and we used such arrays in our search for apoptosis-promoting genes whose expression is regulated by b-HIVS. Our analysis indicated that expression of a gene for a polo-like kinase 1 (PLK1) was significantly suppressed by b-HIVS in U937 and HL60 cells.
Polo-like kinases (PLKs) play critical roles at various stages of mitosis. The polo gene was first identified as an embryonic lethal mutation in Drosophila that caused multiple types of mitotic abnormality, such as formation of multipolar mitotic spindles and the abnormal segregation of chromosomes (Sunkel and Glover, 1988) . Homologs have been identified as PLK1 in mammalian cells, Plx1 in Xenopus, Cdc5p in Saccharomyces cerevisiae, and Plo1 in Schizosaccharomyces pombe (Glover et al., 1998; Nigg, 1998) . All these homologs of PLK1 include a conserved sequence of 30 amino acids, known as a polo box, in addition to a conserved amino-terminal kinase domain (Glover et al., 1998; Nigg, 1998) . Recent studies have shown that homologs of PLK1 are involved in several aspects of the progression of mitosis, including activation of the anaphase-promoting complex (Kotani et al., 1998) , maturation of the centrosome (Lane and Nigg, 1996) , and formation of bipolar spindles (Hamanaka et al., 1995; Glover et al., 1996) . Depletion of Plx1 from extracts of Xenopus oocytes prevents activation of a dual-specificity phosphatase, Cdc25C, that regulates Cdc2 activity, and this observation suggests that Plx might be essential for initiation of the activation loop of Cdc25C (Qian et al., 1998a) . In the absence of PLK function, formation of monopolar spindles is observed (Qian et al., 1998a) . On the other hand, PLKs form a family of strongly conserved serine/threonine kinases and play important roles in various aspects of cell division (Glover et al., 1998; Nigg, 1998) . Several PLK families, including PLK1, PLK2 (Snk), and PLK3 (Prk/ Fnk), have been reported in mammals (Simmons et al., 1992; Clay et al., 1993; Donohue et al., 1995; Li et al., 1996) . Originally, PLK2 and PLK3 were identified as products of immediate-early genes (Simmons et al., 1992; Donohue et al., 1995) , but PLK1 does not share this characteristic. As noted above, the apparent physiological role of PLK1 in progression of the cell cycle has been studied extensively but, by contrast, the functions of PLK3 and PLK2 in the regulation of the cell cycle are poorly understood. In a recent report, it was proposed that PLK3 might function as a tumor suppressor . Overexpression of PLK3 in mammalian cells inhibits proliferation and suppresses colony formation and, in addition, it induces the condensation of chromatin and apoptosis (Conn et al., 2000) . In addition, it was reported that tumor-selective apoptosis was induced in most lines of tumor cells examined, when the function of PLK1 was blocked by expression of a dominant-negative gene (Cogswell et al., 2000) . These results suggest that PLKs might play an important role in the regulation of apoptosis. In the present study, we investigated the possibility that PLK1 might be involved in b-HIVS-induced apoptosis.
Results
Downregulation of expression of the gene for PLK1 in human leukemia HL60 cells upon treatment with b-HIVS b-HIVS inhibits the growth of various lines of cancer cells and is a strong inducer of apoptosis in human leukemia HL60 cells (Hashimoto et al., 1999) . To expand our understanding of the mechanisms responsible for b-HIVS-induced apoptosis, we performed cDNA array analysis using HL60 cells. The Atlas array membranes that we used included 1176 cDNAs for genes that are involved in carcinogenesis, regulation of the cell cycle, and apoptosis. The expression of several of the genes represented on the membranes was affected by the treatment of cells with 10 À6 m b-HIVS for 0.5 h (data not shown). Among these genes, the gene for PLK1 was considered to be of interest because of the important role of PLK1 in the regulation of the cell cycle. Figure 1 shows the results of Northern blotting analysis, with a PLK1-specific probe, of total RNA prepared from HL60 cells that had been treated with 10 À6 m b-HIVS. The level of expression of the PLK1 gene was approximately 60% of that in untreated control cells 0.5 h after the start of exposure of cells to b-HIVS and the level continued to fall gradually with time. By contrast, the expression of GAPDH mRNA was unchanged during the 3 h treatment with b-HIVS.
Effect of b-HIVS on the expression of PLK1 and its kinase activity in human leukemia cells
The observed suppression of expression of the gene for PLK1 in HL60 cells by b-HIVS prompted us to examine the level of PLK1 itself in several lines of human leukemia cells, including HL60 cells, by Western blotting analysis (Figure 2a) . Expression of PLK1 in HL60 cells was clearly reduced after treatment of HL60 cells with 10 À6 m b-HIVS for 0.5 h. A similar result was also observed in human leukemia U937 cells. Expression of PLK1 in U937 cells was strongly suppressed 0.5 h after the start of treatment with b-HIVS. By contrast, we observed no significant suppression of the expression of PLK1 in chronic myeloid leukemia K562 cells. Levels of GAPDH in these cells were unaffected by b-HIVS under the same conditions. Figure 2b shows the effects of b-HIVS on the induction of apoptosis, as judged by DNA fragmentation. The extent of DNA fragmentation in HL60 and U937 cells increased in a time-dependent manner during treatment with b-HIVS, but no significant DNA fragmentation was observed in K562 cells. Since PLK1 has been shown to act through the phosphorylation of certain proteins that are involved in the regulation of the cell cycle (Glover et al., 1998; Nigg, 1998) , we performed a kinase assay in vitro using PLK1-specific antibodies. Figure 2c and d shows the expression of PLK1 and its kinase activity in HEK 293 cells that had been transiently transfected with expression plasmids that encoded PLK1. Mutation of the threonine residue at position 210 to a negatively charged aspartic acid residue (T210D) mimics the effect of phosphorylation of Thr-210 on enzymatic activity (Qian et al., 1998a) . The levels of PLK1 in HEK 293 cells transfected with expression plasmids that encoded PLK1 and PLK1(T210D) were much higher than those in control cells and in cells transfected with the vector alone ( Figure 2c ). As is evident from Figure 2d , PLK1 activity in HEK 293 cells transfected with the expression plasmid that encoded PLK1(T210D) was markedly higher than that in HEK 293 cells transfected with the expression plasmid that encoded PLK1 and that in control cells. Moreover, casein, used as the substrate for PLK1, is phosphorylated by a very limited group of protein kinases, for example casein kinase 2, and addition of a specific inhibitor of casein kinase 2, heparin, did not affect the extent of phosphorylation of casein by PLK1 (data not shown). These results indicate that our system for the determination of kinase activity allowed us specifically to measure the kinase activity of PLK1. Using this system, we examined the protein kinase activity of PLK1 during treatment of cells with b-HIVS ( Figure 2e ). When HL60 and U937 cells were exposed to 10 À6 m b-HIVS, the kinase activity of PLK1 was inhibited within 0.5 h and decreased to 45% in HL60 cells and 21% in U937 cells, of the corresponding activities in untreated control cells. By contrast, treatment of K562 cells with b-HIVS caused only a slight decrease in PLK1 activity. Thus, suppression of the expression of PLK1 and of the kinase activity of PLK1 by b-HIVS was closely correlated with the induction of apoptosis by this compound. Figure 3 shows the expression of PLK1 and its kinase activity in three lines of untreated human leukemia cells. The level of PLK1, as well as its kinase activity, was much higher in K562 cells, which were resistant to the induction of apoptosis by b-HIVS, than in HL60 and U937 cells. Moreover, the kinase activity in HL60 cells was lower than that in U937 and the extent of induction of DNA fragmentation in HL60 cells by b-HIVS was higher than that in U937 cells (Figure 2b ). These observations suggest that a relation might exist between the expression of PLK1 and the resistance of leukemia cells to induction of apoptosis by b-HIVS.
Effects of PLK1-specific antisense ODNs on b-HIVS-induced apoptosis
Since K562 cells had higher PLK1 kinase activity than HL60 and U937 cells and since they were resistant to b-HIVS-induced apoptosis (Figures 2b and 3) , we investigated the effects of PLK1-specific antisense ODNs on cell death. As shown in Figure 4a , treatment of K562 cells with 0.5 mm antisense ODNs significantly increased the extent of cell death and the effect was timedependent, whereas sense ODNs caused only slight increases in cell death. After a 48-h treatment of K562 cells with sense and antisense ODNs, the cells were treated with b-HIVS and incubations were continued for various times (Figure 4b ). When K562 cells that had been treated with antisense ODNs were exposed to 10 À6 m b-HIVS for 12 h, we observed a significant increase in DNA fragmentation, as compared to that in cells exposed to b-HIVS after treatment with vehicle or with sense ODNs. These results suggested that suppression of the expression of PLK1 might play a role in b-HIVS-induced apoptosis.
Inhibitors of tyrosine kinase enhanced b-HIVS-induced apoptosis
In chronic myeloid leukemia (CML) K562 cells, the activity of the tyrosine kinase that is encoded by the Bcr-Abl fusion gene is deregulated. The gene product p210 bcr/abl is responsible for the malignant phenotype of CML and acute lymphoid leukemia (ALL). Recent studies have demonstrated that leukemia cells that express p210 bcr/abl are subject to arrested differentiation and are resistant to apoptosis, even when treated with high doses of antileukemic drugs (McGahon et al., 1994; Effect of b-Hydroxyisovalerylshikonin on the expression of PLK1 Y Masuda et al Bedi et al., 1995) . The results shown in Figure 2b support these earlier findings. To examine whether an inhibitor of tyrosine kinase, genistein, might affect the induction of apoptosis by b-HIVS in K562 cells, we performed an analysis of DNA fragmentation. Genistein is a natural isoflavone compound that specifically inhibits the activities of protein tyrosine kinases (Akiyama et al., 1987) . As shown in Figure 5a (Figure 5b ), while treatment with genistein alone for 12 h caused only 8% DNA fragmentation (data not shown). We next examined the effects of genistein on the activity of PLK1. When K562 cells were treated with genistein for 8 h, the protein kinase activity of PLK1 was significantly suppressed in a dosedependent manner (Figure 5c ). These results suggest that the protein kinase activity of PLK1 might be regulated by protein tyrosine phosphorylation. The results described above demonstrated that the induction of apoptosis in K562 cells was enhanced when tyrosine kinase activity was inhibited by genistein. We also examined the effect of another inhibitor of tyrosine kinase, STI571, which selectively inhibits the tyrosine kinase activity of p210 bcr/abl (Druker and Tamura, 1996) . STI571 is a derivative of 2-phenylamino pyrimidine that preferentially inhibits the growth of Bcr-Abl-positive cells in vitro (Deininger et al., 1997) . Treatment of K562 cells with 0.5 mm b-HIVS alone and with 0.25 mm STI571 alone for 24 h induced minimal DNA fragmentation (7.5 and 4.5%, respectively; Figure 6a ). However, combined treatment with STI571 and 0.5 mm b-HIVS had a synergistic effect on DNA fragmentation in K562 cells. Figure 6b shows the effects of STI571 on DNA fragmentation that was induced by VP16, an inhibitor of topoisomerase II. Treatment with 10 mm VP16 alone induced fragmentation of 4% of the cellular DNA. Treatment of K562 cells with 10 mm VP16 and 0.25 mm STI571 together significantly increased DNA fragmentation, as compared to that observed upon treatment of cells with VP16 alone. Similar synergistic effects on DNA fragmentation were observed with STI571 and VP16 at higher concentrations, such as 25 and 50 mm (Figure 6b ). These results suggest that both b-HIVSinduced and VP16-induced apoptosis could be enhanced by inhibition of the tyrosine protein kinase activity of Bcr/Abl. Therefore, we next examined changes in the tyrosine phosphorylation of proteins in K562 cells that were treated with b-HIVS and STI571 under the same conditions. As shown in Figure 6c , treatment with either b-HIVS or STI571 alone decreased the levels of tyrosine phosphorylation of proteins of 210, 170, and 83 kDa, respectively, suggesting the possibility that b-HIVS might also have the ability to inhibit tyrosine kinase activity. The decrease in tyrosine phosphorylation by STI571 alone was greater than that caused by b-HIVS alone, but treatment with b-HIVS and STI571 together decreased still further the levels of tyrosine phosphorylation of substrate proteins with the same respective molecular weights. In contrast to the results of Figure 6c , VP16 did not affect levels of tyrosine phosphorylation (Figure 6d ). Figure 7 shows the effects of STI571 on the expression of PLK1 and its protein kinase activity. STI571 acted dose-dependently to inhibit the expression of PLK1 in K562 cells (Figure 7a ). In addition, the protein kinase activity of PLK1 was also reduced by such treatment with STI571 (Figure 7b ). We reported previously that b-HIVS-induced apoptosis is inhibited by specific inhibitors of caspase-3 (Hashimoto et al., 1999). We next examined the effects of caspase inhibitors on the b-HIVS-induced suppression of the kinase activity of PLK1 in U937 cells. As shown in Figure 8a , the DNA fragmentation induced by 10 À6 m b-HIVS was inhibited by pretreatment of cells with caspase inhibitors, such as Z-Asp and Z-VAD, in a dose-dependent manner. However, these caspase inhibitors did not affect the suppression of the kinase activity of PLK1 caused by b-HIVS under the same experimental conditions (Figure 8b ).
Various apoptotic stimuli induce the release of cytochrome c from mitochondria and the accumulation of cytochrome c in the cytosol results in the activation of caspase-9, with subsequent activation of caspase-3 (Zou et al., 1997; Perkins et al., 1998) . Since the antiapoptotic protein Bcl-2 is known to prevent the release of cytochrome c and subsequent apoptosis (Gross et al., 1999; Reed, 1999) , we investigated the possibility of a regulatory relation between the expression of Bcl-2 and suppression of the activity of PLK1 during b-HIVSinduced apoptosis. In a previous study, we established two lines of stably transformed U937 cells that express relatively high (U937 bcl-2-2H ) and relatively low (U937 bcl-2-2L ) levels of Bcl-2 . When wildtype U937 cells were treated with 10 À6 m b-HIVS, the DNA fragmentation increased in a time-dependent manner (Figure 8c) . A similar effect of b-HIVS was also observed in U937 cells that had been transfected with the empty vector (U937 V ). However, the induction of DNA fragmentation by b-HIVS was significantly inhibited in U937 bcl-2-2L and U937 bcl-2-2H cells under the same experimental conditions. The inhibitory effects on DNA fragmentation in U937 bcl-2-2H cells were higher than those in U937 bcl-2-2L cells, suggesting that overexpression of Bcl-2 might prevent the induction of apoptosis by b-HIVS.
As shown in Figure 8d , treatment of wild-type U937 cells and U937 V cells with 10 À6 m b-HIVS for 0.5 h resulted in suppression of the kinase activity of PLK1. It is noteworthy that suppression of PLK1 activity was also observed in U937 bcl-2-2H cells during treatment with b-HIVS, even though the b-HIVS-induced DNA fragmentation was inhibited by overexpression of Bcl-2, as described above. These results indicate that the antiapoptotic effects of overexpression of Bcl-2, as well as antiapoptotic effects because of the inhibition of caspases, do not affect the suppression of PLK1 activity that occurs in U937 cells in response to b-HIVS.
Discussion
In a previous study, we showed that, in HL60 cells, b-HIVS has the strongest apoptosis-inducing activity among various derivatives of shikonin and also that b-HIVS inhibits the growth of several lines of human cancer cells (Hashimoto et al., 1999) . In the present study, we examined the genes that are involved in b-HIVS-induced apoptosis in HL60 cells using geneexpression arrays and found that b-HIVS altered the expression of the gene for PLK1, which is involved in regulation of the cell cycle (Hamanaka et al., 1995; Glover et al., 1996; Lane and Nigg, 1996; Kotani et al., 1998) . The level of expression of the gene for PLK1 began to decrease within 0.5 h of the start of treatment Expression of PLK1 and its kinase activity also decreased under the same experimental conditions. PLK1 is known to perform its various roles at different phases of mitosis by phosphorylating several proteins that include cdc25 (Hamanaka et al., 1995; Glover et al., 1996; Lane and Nigg, 1996; Kotani et al., 1998) . Ectopic expression of PLK1 has been shown to transform NIH3T3 cells (Smith et al., 1997) . Recently, a new aspect of the function of PLK1 was described: when PLK1 function was blocked by delivery of a dominant-negative gene via an adenoviral vector, tumor-selective apoptosis was observed in various lines of tumor cells (Cogswell et al., 2000) . By contrast, normal human mammary epithelial cells were arrested in mitosis and appeared to escape the mitotic catastrophe that occurred in tumor cells under the same experimental conditions. Taken together, these results indicate the involvement of PLK1 in cell growth, cell death, and transformation via the phosphorylation of proteins that are associated with the cell cycle.
In the present study, we demonstrated that b-HIVS inhibits the activity of PLK1 in HL60 and U937 cells. Furthermore, treatment with PLK1-specific antisense ODNs sensitized K562 cells to b-HIVS-induced apoptosis, indicating that suppression of the expression and activity of PLK1 by b-HIVS is involved in apoptosis.
PLKs form an evolutionarily conserved family and, to date, three PLKs, namely, PLK1, PLK2, and PLK3, have been identified in mammals (Simmons et al., 1992; Clay et al., 1993; Donohue et al., 1995; Li et al., 1996) . Each PLK appears to play a role in the progression of cell cycle, but it is likely that each has a different function. PLK1 is the most extensively studied PLK and is important for several aspects of the progression of mitosis, as noted above. In contrast to PLK1, PLK3 (previously designated Prk) has been suggested to be a tumor suppressor . Overexpression of PLK3 in HeLa cells suppresses proliferation and the ectopic expression of PLK3 induces the condensation of chromatin and apoptosis (Conn et al., 2000) . It remains to be determined whether b-HIVS affects the activity of PLK3 during apoptosis.
The results in Figure 2b indicate that K562 cells that express high levels of Bcr-Abl require higher doses of b-HIVS for induction of apoptosis than those required to induce apoptosis in U937 and HL60 cells. These results are consistent with the finding that expression of BcrAbl renders tumor cells resistant to various chemotherapeutic agents (McGahon et al., 1994; Bedi et al., 1995) . Several antiapoptotic factors act downstream of BcrAbl tyrosine kinase. It has been suggested that Bcr-Ablmediated transformation and resistance to apoptosis might be associated with constitutively increased activities of Akt kinase and NF-kB (Hamdane et al., 1997; Skorski et al., 1997) . Akt kinase has been shown to suppress apoptosis, but details of the mechanism remain to be elucidated (Datta et al., 1999) . The kinase activity of PLK1 was also higher in K562 cells than in HL60 and U937 cells, suggesting the possibility that a high-level activity of PLK1 might be involved in antiapoptotic effects, as in the case of Akt kinase. The results in Figure 7 , obtained with PLK1-specific antisense ODNs, support this possibility.
In recent clinical trials, STI571, a specific inhibitor of the Bcr-Abl tyrosine kinase, exhibited significant activity in Ph + acute leukemia cells, as well as at all phases of CML (Druker et al., 1999) . There is evidence to suggest that treatment of CML with STI571 and Ara-C, IFN, or DNR might be more effective than treatment with STI571 alone (Thiesing et al., 2000) . We found that b-HIVS and STI571 had synergistic effects on the induction of apoptosis in K562 cells and this finding suggests that the combination of STI571 and b-HIVS might be useful in a clinical setting as a treatment for CML. However, details of the molecular mechanism of the antileukemic activity of b-HIVS remain to be elucidated. Both b-HIVS and STI571 separately inhibited tyrosine phosphorylation in K562 cells. When K562 cells were treated with STI571 alone, the extent of the tyrosine phosphorylation of cellular proteins declined. Moreover, inhibition of tyrosine phosphorylation by STI571 was significantly enhanced in the presence of b-HIVS. By contrast, VP16 did not affect the extent of tyrosine phosphorylation, even though VP16-induced apoptosis was increased in the presence of STI571. These results suggest that b-HIVS might inhibit Bcr-Abl or other tyrosine protein kinases. Indeed, b-HIVS inhibits the activity of several tyrosine kinases, such as v-Src and a receptor for EGF in vitro (Hashimoto et al., 2002) . Thus, it is likely that tyrosine kinases are possible targets of b-HIVS. It is now necessary to identify the specific tyrosine kinase(s) that is the actual target of b-HIVS and to study the physiological significance of the inhibition of its activity by b-HIVS. The activities of PLKs are regulated by several factors, which include DNA damage and phosphorylation. Cdc5, the homolog in Saccharomyces cerevisiae of PLK, is modified post-translationally in response to DNA damage (Cheng et al., 1998) . In addition, PLK1 is a target of the G 2 -M DNA damage checkpoint (Smits et al., 2000) . Such findings are correlated with our preliminary observations that PLK1 activity is suppressed by treatment of human leukemia U937 cells with VP16 or with camptothecin (data not shown). Moreover, Xenopus polo-like kinase 1 (Plx1) is activated by phosphorylation, and a polo-like kinase kinase 1 (Plkk1) that was recently isolated from Xenopus was able to phosphorylate and activate Plx1 in vitro (Qian et al., 1998b) . In the present study, we demonstrated that inhibitors of tyrosine kinase reduce the kinase activity of PLK1 in K562 cells. Thus, tyrosine kinases appear to be located upstream of signaling cascades that regulate PLK1 activity. STI571 selectively inhibits the tyrosine kinase activity of Bcr-Abl, of c-Kit tyrosine kinases, and of the receptor for platelet-derived growth factor (Druker and Tamura, 1996) . We found that PLK1 kinase activity was reduced by STI571 in K562 cells, suggesting that Bcr-Abl might be one of the tyrosine kinases involved in the regulation of the activity of PLK1. By contrast to the effect of STI571, PLK1 activity was unaffected by treatment of U937 cells with vincristine, an agent that interferes with microtubules, even though apoptosis was strongly induced (data not shown). If tubulins are downstream targets of PLK1 (Feng et al., 1999) , vincristine should affect the assembly of microtubules directly and might be able to induce apoptosis without affecting the kinase activity of PLK1. We also examined the possible relation between the antiapoptotic effect of Bcl-2 and suppression of PLK1 activity by b-HIVS. Bcl-2 protein exerts its antiapoptotic effect by inhibiting the release of cytochrome c from mitochondria (Gross et al., 1999; Reed, 1999) . We found that b-HIVS-induced apoptosis in U937 cells was inhibited by high levels of Bcl-2 protein, and it is possible that b-HIVS-induced apoptosis might be blocked by interference with the release of cytochrome c from mitochondria. However, overexpression of Bcl-2 in U937 cells had no effect on the b-HIVS-induced suppression of PLK1 activity. Caspase inhibitors, which prevented b-HIVS-induced apoptosis, also did not affect the suppression of PLK1 activity. These observations suggest that the effect of b-HIVS on PLK1 activity occurs upstream of mitochondria.
In conclusion, our data suggest that b-HIVS suppresses PLK1 activity in addition to inducing apoptosis in human leukemia HL60 and U937 cells. The b-HIVSmediated decrease in the kinase activity of PLK1 is probably responsible for the induction of apoptosis, since PLK1-specific antisense ODNs reduced the apoptosis-inducing effects of b-HIVS in K562 cells. Inhibition of Bcr-Abl tyrosine kinase activity by STI571 inhibited the kinase activity of PLK1 and sensitized K562 cells to b-HIVS-induced apoptosis, suggesting the involvement of tyrosine kinases in the regulation of PLK1 kinase activity. b-HIVS and STI571 had synergistic effects in terms of the induction of apoptosis. While results in vitro cannot predict the results of clinical trials, our findings might be relevant to attempt to improve treatment of CML and Ph + ALL.
Materials and methods

Reagents, cell lines and cell culture
Genistein, VP16, and dephosphorylated casein were purchased from Sigma (St Louis, MO, USA (Hashimoto et al., 1999) , and dissolved in ethanol at a concentration of 10 À2 m for use as a stock solution. STI571, kindly provided by Novartis (Basel, Switzerland), was prepared as a 10 À2 m stock solution in sterile phosphatebuffered saline. Human leukemia cell lines (HL60, U937, and K562) and human embryonic kidney (HEK) 293 cells were provided by the Japanese Cancer Resource Bank. All lines of cancer cells were maintained in RPMI 1640 medium (GIBCO, Glasgow, UK) supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml of penicillin, and 100 mg/ml streptomycin, in an atmosphere of 5% CO 2 at 371C. Cells were seeded at a concentration of 2-3 Â 10 5 cells/ml and maintained logarithmic growth by passing them every 2-3 days. Cell viability was checked by the trypan blue exclusion method.
Analysis of DNA fragmentation
The extent of DNA fragmentation was determined by Wyllie's method with slight modifications (Wyllie, 1980) . Cells, collected by centrifugation, were suspended in lysis buffer [5 mm Tris-HCl (pH 7.4), 1 mm EDTA, 0.5% Triton X-100] and incubated for 20 min on ice. The suspension was centrifuged at 27 000 g for 20 min and the fragmented DNA was recovered from the supernatant. The pellet remaining in the centrifugation tube was sonicated for 60 s at 36.5 kHz. The amount of total DNA was determined by fluorometric method with DAPI, which has an affinity for A-T-rich regions of DNA (Brunk et al., 1979) . The intensity of fluorescence was measured at 454 nm with excitation at 362 nm. The extent of DNA fragmentation was defined as the ratio of the amount of fragmented DNA to the total amount of DNA.
Northern blotting analysis
Total RNA was prepared by acid guanidinium thiocyanatephenol-chloroform extraction (Chomczynski and Sacchi, 1987) , and aliquots of 10 mg per lane were fractionated on a 1% formaldehyde-agarose gels (Lehrach et al., 1977) . RNA was blotted onto a nylon membrane and allowed to hybridize with a radiolabeled probe that had been prepared by random priming (Thomas, 1980; Feinberg and Vogelstein, 1983) .
Procedures for cDNA array analysis
All procedures for cDNA array analysis were performed according to the instructions from the manufacturer of the arrays. PolyA + mRNA was isolated from b-HIVS-treated and untreated HL60 cells, and radiolabeled cDNA was prepared with [a-32 P]dATP using the Total RNA Labeling System. Cancer 1.2 Atlas array nylon membranes were incubated initially for 30 min at 681C in ExpressHyb hybridization solution that contained 100 mg/ml salmon testis DNA. The radiolabeled probes were added to the hybridization solution and incubation was continued overnight at 681C. The array membranes were then washed three times with 2 Â salinesodium citrate buffer (SSC) that included 1% sodium dodecyl sulfate (SDS) at 681C twice with 0.1 Â SSC that included 1% SDS at 681C and finally with 2 Â SSC at room temperature.
The membranes were scanned with a Storm Phosphorimager (Molecular Dynamics, CA, USA) after 48 h exposure to a Phosphorimager screen. Images were analysed with the AIS system (Imaging Research Inc.).
Preparation of cell lysates
Cells were washed twice with PBS and lysed in lysis buffer (10 mm Tris-HCl, pH 7.4, 1 mm EDTA, 1 mm EGTA, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin A, 5 mg/ml antipain, 50 mm NaF, 2 mm sodium orthovanadate, 10 mm sodium pyrophosphate, 0.15 m NaCl, 1% Triton X-100, and 0.5 mm PMSF). The lysate was centrifuged at 15 000 g for 15 min and the supernatant was used for Western blotting analysis and assay of kinase activity.
Western blotting analysis
A cell lysate containing 50 mg of protein was fractionated by SDS-PAGE and then proteins were transferred to a polyvinylidene difluoride membrane. The membrane was first rinsed with TBST (20 mm Tris-HCl, pH 7.4, 0.15 m NaCl, 0.1% Tween 20) and then blocked with 3% (w/v) bovine serum albumin in TBST for 1 h at room temperature. The blocked membrane was subsequently probed for 1 h at room temperature with antibodies against either human PLK1 or phosphotyrosine (PY20) in TBST. After the membrane had been washed four times with TBST, it was incubated for 1 h at room temperature either with horseradish peroxidase-conjugated donkey antibodies against goat IgG (Santa Cruz, CA, USA) for detection of PLK1 or with horseradish peroxidaseconjugated goat antibodies against mouse IgG (American Qualex, La Mirada, CA, USA) for detection of phosphotyrosine. After the membrane had been washed with TBST, bands of protein on the membrane were visualized with an ECL Western blotting detection kit.
Assay of PLK activity
Lysis and all immunoprecipitation procedures were performed at 41C. Supernatants obtained from lysed cells were incubated with PLK1-specific antibodies for 1 h and then protein GSepharose beads (Amersham Pharmacia Biotech, AB, Canada) were added. Each mixture was incubated at 41C for 1 h and then beads were washed three times with lysis buffer. Assays of PLK activity were performed in 20 ml aliquots of kinase cocktail, which contained 50 mm Tris-HCl (pH 7.5), 10 mm MgCl 2 , 5 mm dithiothreitol, 2 mm EGTA, 0.5 mm Na 3 VO 4 , 3 mg of dephosphorylated casein, and 20 mm [g-32 P]ATP (2 mCi). After a 30-min incubation at 301C, the reaction was terminated by the addition of 10 Â sample buffer for SDS-PAGE, and the reaction mixture was fractionated by SDS-PAGE. Products of phosphorylation were visualized by autoradiography.
Treatment of human leukemia K562 cells with antisense oligonucleotides
We used 19-mer oligonucleotides (ODNs) that corresponded to the middle region of the human gene for PLK1, as reported previously by Elez et al. (2000) . The sequences of the ODNs were as follows: PLK1 antisense, 5 0 -CCTGACCAGCC-CACGCTCC-3 0 ; and PLK1 sense, 5 0 -GGAGCGTGGGCTG GTCAGG-3 0 . All ODNs had fully modified phosphorothioate backbones. K562 cells were treated with ODNs according to the instructions provided with the DOTAP transfection reagent (Roche Diagnostics) with slight modifications. K562 cells were treated with 500 nm ODNs in serum-free RPMI 1640 medium in the presence of the N-[1-(dioleoyloxy) propyl]-N,N,N-trimethylammonium methyl sulfate (DOTAP). After a 4-h incubation at 371C, the medium containing the DOTAP/ ODN mixture was replaced by RPMI 1640 medium that contained 10% FCS and cells were incubated for a further 24-48 h. Then, cell viability and apoptosis were examined by staining with trypan blue and estimation of the extent of DNA fragmentation, respectively.
Transfection of HEK 293 cells
HEK 293 cells were transfected with expression plasmids using Effectene transfection reagent, according to the manufacturer's instructions.
Expression plasmids and mutagenesis
cDNA for human PLK1 was obtained from total RNA, isolated from human leukemia HL60 cells, by RT-PCR with primers that contained a 5 0 ATG initiation codon and a 3 0 TAA termination codon, namely, 5 0 -AGAATTCAATGACT GCAGCGGTGACTG-3 0 and 5 0 -AGAATTCTTAGGAGG CCTTGAGACGG-3 0 , respectively. The product of PCR was cloned into the EcoRI site of the pIRES2-EGFP expression vector (Clontech, Palo Alto, CA, USA). The T210D mutant of human PLK1 was created by PCR with the following pair of primers: 5 0 -GGAGAGGAAGAAGGACCTGTGTGGGAC-3 0 and 5 0 -GCTCCACACAGGTCCTTCTTCCTCTCC-3 0 .
